Another preclinical study has shown that SRF617, a fully human anti-CD39 antibody, synergizes with PD-1 checkpoint inhibitors to enhance anti-tumor efficacy and improve overall survival [99]. The gene discussed is ENTPD1; the disease is neoplasm.